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Summary
Recent clinical trials have demonstrated that it is possible to induce durable remission in several tumors (non-small 
cell lung cancer (NSCLC), melanoma, squamous cancer of head and neck, renal cell carcinoma, Hodgkin lymphoma, 
colorectal cancer) by blocking the PD-1/PD-L1 (programmed death-1/programmed death-ligand 1) axis with anti-PD-1 or 
anti- PD-L1 antibodies and that an objective clinical response was closely associated with immunohistochemical PD-L1 
 expression in tumor cells. Because immunohistochemistry is widely accepted and used method for PD-L1 assessment it is 
important to defi ne criteria for selecting patients who are candidates for immunotherapy and can benefi t from it.
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IMUNOHISTOKEMIJSKA IZRAŽENOST PD-L1 U SOLIDNIM TUMORIMA
Sažetak
Posljednjih godina klinička istraživanja su pokazala da je moguće postići trajniju remisiju kod nekoliko vrsta solidnih 
tumora (karcinom pluća ne-malih stanica (NSCLC), melanom, pločasti karcinom glave i vrata, renalni karcinom, urotelni 
karcinom, Hodgkin limfom, kolorektalni karcinom) blokirajući aktivaciju PD-1/PD-L1 (engl. programmed death- 1/programmed 
death-ligand 1) signalnog puta primjenjujući anti-PD-1 i anti-PD-L1 protutijela. Učinak terapije usko je povezan s izraženošću 
PD-L1 u tumorskim stanicama. Iako su mehanizmi kojima tumorske stanice izražavaju PD-L1 dobro poznati, studije su do 
sada pokazale da samo manji broj pacijenata može imati koristi od PD-1/PD-L1 imunoterapije, vezano uz izraženost PD-L1 
na tumorskim stanicama. Stoga je važno odrediti kriterije za odabir pacijenata koji mogu imati koristi od imunoterapije.
KLJUČNE RIJEČI: PD-1/PD-L1 signalni put, immunoterapija, imunohistokemija, solidni tumori
INTRODUCTION
As cancer therapy has recently focused on 
immunotherapy, driving eff orts on immune 
checkpoint inhibitors in order to enhance the im-
mune response against tumor cells, pathologists 
are challenged to bring results that will help in 
choosing patients who will benefi t from therapy. 
A large number of studies is focused on Pro-
grammed cell death 1 (PD-1) and its ligand 
 Programmed cell death ligand 1 (PD-L1/B7-H1/
CD274) because of the involvement of this path-
way in downregulating intensity and duration of 
T-cells immune responses. Once activated, PD-1/
PD-L1 pathway inhibits T-cells proliferation and 
survival as well as the eff ect or functions such as 
cytotoxicity and cytokine release (1).
PD-1 is a member of the immunoglobulin 
gene family and several studies demonstrated its 
expression on the surface of activated T cells, acti-
vated B cells, regulatory T-cells (Treg) and natural 
killer cells (NK). It has two ligands, PD-L1 and 
PD-L2 and when the T-cell receptor PD-1 binds to 
its ligands on antigen presenting cells (APC), the 




PD-L1 (B7-H1 or CD274) is a cell surface gly-
coprotein that is mainly expressed in placenta, 
tonsil and retina, all implicated in immune toler-
ance mechanism: protein can also be expressed on 
hematopoietic cells (dendritic, myeloid, T and B 
cells), non-hematopoietic cells and on tumor cells 
(3). PD-L1 mRNA is expressed in almost all hu-
man tissues but cell membrane protein expression 
is confi ned to specifi c groups of cells. Then, it is 
conceivable that PD-L1 mRNA regulation is nor-
mally depending on post-transcriptional regula-
tion. On the other side, the protein can be ex-
pressed on diff erent types of cancer cells (4). Anti-
bodies that target either PD-1 or PD-L1 will block 
this ligand-receptor interface, thereby allowing T 
cells to att ack the tumor and increase antitumor 
immune response. Recent clinical trials have dem-
onstrated that it is possible to induce durable re-
mission in several tumors (non-small cell lung 
cancer (NSCLC), melanoma, renal cell carcinoma) 
by blocking the PD1/PD-L1 axis with anti-PD-1 or 
anti- PD-L1 antibodies and that an objective clini-
cal response was closely associated with immuno-
histochemical PD-L1 expression in tumor cells (5). 
Immunohistochemistry is widely accepted and 
used method for PD-L1 assessment. However, cri-
teria for selecting patients who are candidates for 
immunotherapy, and can benefi t from it, are still 
debated and are very diverse depending on histo-
logical type of tumor as well as on antibody used 
(further depending on drug planned to use). There 
are some specifi c issues related to PD-L1 expres-
sion and results of evaluation. Recent studies fo-
cused on some important patients aspects like age, 
weight and microbiota emphasizing how they can 
deeply infl uence immune reaction to cancer and 
therefore, the response to immunotherapy (6). On 
the other hand, there are many factors that can in-
fl uence PD-L1 expression evaluation. It is impor-
tant, for now, that every anti PD-1/PD-L1 agent 
requires its own companion immunohistochemi-
cal diagnostics, meaning that for each drug there 
is specifi c antibody clone for immunohistochemis-
try as well as evaluation protocol.
One among many questions concerning PD-
L1 immunohistochemistry evaluation is which 
kind of sample should be collected: small biopsy 
or surgical resection material. Formalin fi xed par-
affi  n embedded tissue is appropriate for analysis 
as well as fresh tissue specimens. Rehman JA et al. 
study shows that single paraffi  n block with surgi-
cally resected tumor tissue may be representative 
of the larger tumor and that 90% of the heteroge-
neity is presented in a single slide, at the millime-
ter level (7). On small biopsy fragments, like bron-
chial or transthoracic biopsies, the expression of 
PD-L1 can be overestimated but more often un-
der-estimated compared to the expression of large 
tumor sections and certain patients may not re-
ceive suffi  cient treatment. Also the proportion of 
tumor and stromal cells can diff er from one tumor 
to another and the percentage of tumor cells can 
vary from 1 to 2% up to almost 100% (8).
Because PD-L1 is tumor marker represented 
as biological continuum of protein expression 
from very low levels through moderate to very 
high levels, result of immunohistochemical evalu-
ation is percentage of positive cells, where positiv-
ity is seen as membrane staining, meaning that 
cytoplasmic staining is excluded from positive re-
sult. Most recent studies do not integrate intensity 
reporting into pathology report (9). Analysed cells 
can be tumor cells or tumor associated immune 
cells or both. In tumors like melanoma, colorectal 
cancer or NSCLC analysed cells are tumor cells 
while analysing urothelial carcinoma staining of 
tumor associated immune cells has to be found for 
claiming positive result. Clinical trials show that 
diff erent drugs and diff erent tumors have diff er-
ent cutoff s defi ning positive and negative groups 
of patients. That scale of positivity makes PD-L1 
imperfect marker. So the question is how to defi ne 
a threshold for positive PD-L1 labeling on biopsy 
tissue samples, taking into account that certain pa-
tients respond to treatment targeting PD-L1/PD-1, 
despite low or absent immunoreactivity of this 
biomarker (10). For diff erent studies and antibody 
clones used, the threshold to call PD-L1 expres-
sion positive by immunohistochemistry diff ers. 
While in some studies, a threshold of 50% for tu-
mor cells (like NSCLC) or of 5% for tumor associ-
ated immune cells (like for urothelial carcinoma) 
was related to optimal response to therapy, other 
studies set a lower threshold of 1% of positive tu-
mor cells (like melanoma) (11,12). In comparison, 
tumor histologies currently thought to be less re-
sponsive to immune checkpoint inhibition, such 
as colorectal cancer and sarcoma, showed tumor 
PD-L1 expression ranging between 12%–53%, in-
dicating that tumor PD-L1 immunohistochemical 
expression is not the sole determinant of which 




PD-L1 is a heterogeneous and dynamic mar-
ker, meaning that within the same tumor expres-
sion can vary according to tumor diff erentiation 
(5). In tumor cells PD-L1 expression can change 
during and after treatment infl uenced by the ad-
ministrated drugs and by immune state of the or-
ganism. Indeed, chemotherapy or target therapy 
may induce PD-L1 expression in immune thera-
py-naive tumors (14).
Study conducted on cell lines from non-small 
cell lung carcinoma (NSCLC) showed the eff ects 
of diff erent chemotherapies on PD-L1 expression. 
It has been shown that doxorubicin can down-reg-
ulate membranous PD-L1 expression on cancer 
cells and that etoposide and paclitaxel are able to 
induce PD-L1 expression on cancer cells (15).
Another question is whether primary tumors 
diff er in PD-L1 expression from their correspond-
ing metastases. Jilaveanu et al. conducted a study 
on a series of primary clear cell renal cell carcino-
ma and matched metastases which showed great-
er PD-L1 expression in metastatic tumor than pri-
maries (16). Another recent study has also demon-
strated diff erence in PD-L1 expression between 
primary and metastatic of a series of primary clear 
cell RCC and corresponding metastases (2). Stud-
ies like these show that it might be signifi cant to 
assess PD-L1 expression on the primary tumor as 
well as on metastatic lesion.
CONCLUSION
Concerning all above mentioned it is clear that 
many further investigations are needed in order to 
establish standard and reproducible criteria for PD-
L1 detection and to bett er select the target patients 
acceptable for anti PD-1 or anti PD-L1 therapy.
REFERENCES
 1.  Sholl LM, Aisner DL, Allen et al. Programmed Death 
Ligand-1 Immunohistochemistry-A New Challenge 
for Pathologists. A Perspective From Members of the 
Pulmonary Pathology Society. Arch Pathol Lab Med 
2016;140:341-4.
 2.  Callea M, Pedica F, Doglioni C. Programmed death 1 
(PD-1) and its ligand (PD-L1) as a new frontier in can-
cer Immunotherapyand challenges for the Pathologist: 
state of the art. Pathologica 2016;108:48-58.
 3.  McDermott  DF, Atkins MB. Immune therapy for kid-
ney cancer: a second dawn? Semin Oncol 2013;40:
492-8.
 4.  Chen L, Han X. Anti-PD-1/PD-L1 therapy of human 
cancer: past, present, and future. J Clin Invest 2015;
125:3384-91.
 5.  Lin Z, Xu Y, Zhang Y et al. The prevalence and clinico-
pathological features of programmed death-ligand 1 
(PD-L1) expression: a pooled analysis of literatures. 
Oncotarget 2016;7:15033–15046.
 6.  Klevorn LE, Teague RM. Adapting cancer immuno-
therapy models for the real world. Trends Immunol 
2016;37:354-63.
 7.  Rehman JA, Han G, Carvajal-Hausdorf DE. Quantita-
tive and pathologist-read comparison of the heteroge-
neity of programmed death-ligand 1 (PD-L1) expres-
sion in non-small cell lung cancer. Mod Pathol 2017;
30:340-9.
 8.  Planchard D, ShtivelbandM, Shi K et al. A phase III 
study of MEDI4736 (M), an anti-PD-L1 antibody, in 
monotherapy or in combination with tremelimumab 
(T), versus standard of care (SOC) in patients (pts) 
with advanced non smallcell lung cancer (NSCLC) 
who have received at least two prior systemic treat-
ment regimens (ARCTIC). J Clin Oncol 2015;33 (suppl; 
abstr TPS8104)
 9.  Hamanishi J, Mandai M, Matsumura N, et al. PD-1/
PD-L1 blockade in cancer treatment: perspectives and 
issues. Int J Clin Oncol 2016;21:462-73.
10.  Keff ord R, Ribas A, Hamid O et al. Clinical effi  cacy 
and correlation with tumor PD-L1 expression in pa-
tients (pts) with melanoma (MEL) treated with the 
anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol 
2014;32:5s (suppl; abstr 3005)
11.  Horn L, Spigel DR, Gett inger SN et al. Clinical activity, 
safety and predictive biomarkers of the engineered 
antibody MPDL3280A (anti-PDL1) in non-small cell 
lung cancer(NSCLC): update from a phase Ia study. J 
Clin Oncol 2015;33 (suppl;abstr 8029)
12.  Spira AI, Park K, Mazières J et al.Effi  cacy, safety and 
predictive biomarkerresults from a randomized phase 
II study comparing atezolizumab vs docetaxel in 2L/3L 
NSCLC (POPLAR). J Clin Oncol 2015 (suppl abstr 8010)
13.  Patel SP, Razelle Kurzrock R.PD-L1 Expression as a 
Predictive Biomarker in Cancer Immunotherapy.Mol 
Cancer Ther 2015;14:847-56.
14.  Kerr KM, Tsao MS, Nicholson AG, et al. Programmed 
death-ligand 1 immunohistochemistry in lung cancer: 
in what state is thisart? J Thorac Oncol 2015;10:985-9.
15.  Champiat S, Ileana E, Giaccone G et al. Incorporating 
immune-checkpointinhibitors into systemic therapy 
of NSCLC. J Thorac Oncol 2014;9:144-53.
16. Jilaveanu LB, Shuch B, Zito CR, et al. PD-L1 expression 
in clear cell renal cell carcinoma: an analysis of nephrec-
tomy and sites of metastases. J Cancer 2014;5:166-72.
Corresponding author: Petra Radulović, Clinical Depart-
ment of Pathology Ljudevit Jurak, Sestre milosrdnice Uni-
versity Hospital Center, Vinogradska 29, Zagreb, Croatia. 
e-mail: pradulovi@gmail.com
